← All trials
NCT05431582
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 14, 2022
- Primary completion
- Dec 14, 2022
- Completion date
- Dec 14, 2022
- First posted
- Jun 24, 2022
- Last posted
- Dec 26, 2022
- Enrollment
- 0
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Texas at HoustonLead sponsor
- University of Texas at HoustonOverall official - principal investigator
- Zentalis PharmaceuticalsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.